Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo

International Journal of Oncology

Volumn 28, Issue 2, 2006, Pages 439-446

  Michaelis, Martin ^a   Fichtner, Iduna ^b   Behrens, Diana ^b   Haider, Wolfram ^d   Rothweiler, Florian ^a   Mack, Andreas ^c   Cinatl, Jaroslav ^a   Doerr, Hans Wilhelm ^a   Cinatl Jr , Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Gamma Knife Zentrum Frankfurt   (Germany)

^d Institute for Animal Pathology   (Germany)

Author keywords

Bortezomib; Chemoresistance; Doxorubicin; Multidrug resistance; Neuroblastoma; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ATP DEPENDENT 26S PROTEASE; BORONIC ACID DERIVATIVE; BORTEZOMIB; DOXORUBICIN; PROTEASOME; PYRAZINE DERIVATIVE; VINCRISTINE;

ANIMAL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; VINCRISTINE;

EID: 33646789993     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.2.439     Document Type: Article

References (44)

1. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H and Chauvin F: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16: 953-965, 1998.
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1113, 1999.
3. Weinstein JL, Katzenstein HM and Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8: 278-292, 2003.
4. Keshelava N, Seeger RC, Groshen S and Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405, 1998.
5. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417-421, 2004.
6. Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639, 2005.
7. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C and McConkey DJ: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2: 835-843, 2003.
8. Richardson PG, Mitsiades C, Hideshima T and Anderson KC: Proteasome inhibition in the treatment of cancer. Cell Cycle 4: 290-296, 2005.
9. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM and White E: Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7: 227-238, 2005.
10. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
11. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M and Adamson PC: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22: 4804-4809, 2004.
12. Kotchetkov R, Hernáiz Driever P, Cinatl J, Michaelis M, Karaskova J, Blaheta RA, Squire JA, von Deimling A, Moog J and Cinatl J Jr: Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp Expression. Int J Oncol 27: 1029-1037, 2005.
13. Cinatl J Jr, Cinatl J, Kotchetkov R, Matousek J, Woodcock BG, Koehl U, Vogel JU, Kornhuber B and Schwabe D: Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs. Anticancer Res 20: 853-859, 2000.
14. Michaelis M, Cinatl J, Vogel JU, Pouckova P, Hernáiz Driever P and Cinatl J Jr: Treatment of drug-resistant human neuroblastoma cells with cyclodextrin inclusion complexes of aphidicolin. Anticancer Drugs 12: 467-473, 2001.
15. Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T and Cinatl J Jr: Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104: 36-43, 2003.
16. LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB and Biedler JL: Multidrug resistance in human neuroblastoma cells. J Pediatr Surg 26: 1107-1112, 1991.
17. Cinatl J Jr, Cinatl J, Kotchetkov R, Vogel JU, Woodcock BG, Matousek J, Pouckova P and Kornhuber B: Bovine seminal ribonuclease selectively kills human multidrug-resistant neuroblastoma cells via induction of apoptosis. Int J Oncol 15: 1001-1009, 1999.
18. Tweddle DA, Malcolm AJ, Bown N, Pearson AD and Lunec J: Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61: 8-13, 2001.
19. Russell J, Wheldon TE and Stanton P: A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res 55: 4915-4921, 1995.
20. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C and Lunec J: The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197: 93-98, 2003.
21. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
22. Michaelis M, Suhan T, Cinatl J, Hérnaiz Driever P and Cinatl J Jr: Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25: 1795-1799, 2004.
23. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
24. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
25. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin AS Jr: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61: 3535-3540, 2001.
26. Yu J, Tiwari S, Steiner P and Zhang L: Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2: 694-699, 2003.
27. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL and Koeffler HP: Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24: 344-354, 2005.
28. Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, de The H, Hermine O and Bazarbachi A: Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 24: 419-430, 2005.
29. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM and Perez-Soler R: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154, 2003.
30. Williams SA and McConkey DJ: The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 63: 7338-7344, 2003.
31. Okada H and Mak TW: Pathways of apoptotic and nonapoptotic death in tumour cells. Nat Rev Cancer 4: 592-603, 2004.
32. Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638-2645, 1999.
33. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J and Callery MP: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82: 110-122, 2001.
34. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001.
35. Le Blanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC and Anderson KC: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002.
36. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J and McConkey DJ: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1: 1243-1253, 2002.
37. Amiri KI, Horton LW, LaFleur BJ, Sosman JA and Richmond A: Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64: 4912-4918, 2004.
38. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S and Matsuoka M: Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18: 1357-1363, 2004.
39. Boccadoro M, Morgan G and Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5: 18, 2005.
40. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T and Bibby M: Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40: 298-307, 2004.
41. Koike M, Fujita F, Komori K, Katoh F, Sugimoto T, Sakamoto Y, Matsuda M and Fujita M: Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. Cancer Sci 95: 541-546, 2004.
42. Brown JM and Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5: 231-237, 2005.
43. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F and Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23: 667-675, 2005.
44. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D and Zelenetz AD: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23: 676-684, 2005.